Please update your Flash Player to view content.

Bio Pro Classes:

 
Monday, 01 Jun 2015 - Tuesday, 02 Jun 2015
Category: Bio Pro Classes

 
Wednesday, 03 Jun 2015 - Friday, 05 Jun 2015
Category: Bio Pro Classes

 
Friday, 05 Jun 2015
Category: Bio Pro Classes

 
Monday, 08 Jun 2015
Category: Bio Pro Classes

 
Wednesday, 10 Jun 2015
Category: Bio Pro Classes

 
Wednesday, 10 Jun 2015
Category: Bio Pro Classes

 
Thursday, 11 Jun 2015
Category: Bio Pro Classes

 
Thursday, 11 Jun 2015
Category: Bio Pro Classes

 
Tuesday, 16 Jun 2015 - Wednesday, 17 Jun 2015
Category: Bio Pro Classes

Event Registration Cart

Your cart is empty.

2015LegDayWebsiteInfo2

It is critical that House & Senate patent litigation reform bills currently under consideration provide a fair mechanism for patent owners to defend their patents and balance the inter partes review (IPR) proceedings by harmonizing PTO standards/processes with those used in court.

The attached letter will be sent to all members of Oregon’s congressional delegation on behalf of Oregon Bioscience Association and individual members. Please reply to This email address is being protected from spambots. You need JavaScript enabled to view it.with your permission to list your individual company by Thursday, May 28.

OR Bio 2014-’15 Annual Report: The Thriving Bio Ecosystem

In 2014, Oregon held steady with a 6% net increase in federal grants from several funding sources such as the National Institutes of Health (NIH), Small Business Technology Transfer Program (STTR), Small Business Innovation Research (SBIR), Department of Defense, and the National Science Foundation.


photo- front page AR 2014-15

View PDF

All Together now:  Can Oregonians sync up their medications?

‘Yes,’ says Sen. Alan Bates to the Oregon legislature’s consideration of a bill supported by
Sen. Bates and more than a dozen patient advocate groups that helps patients coordinate
their medications to both improve compliance and safety

CAN OREGONIANS SYNC UP THEIR MEDICATIONS

View PDF

 ____________________________________________________________________
                                                

Bio in the High Desert - Smashing success

Bio in the High Desert, held at McMeniman's St. Francis School in Bend this past Monday, May 18th, was a smashing success. More than 70 attendees took advantage of this annual opportunity to both network and receive an update from EDCO Executive Director Roger Lee and Oregon Bio Executive Director Dennis McNannay.

IMG 3838colorcorrected IMG 3839resized

 IMG 3834Colorcorrected IMG 3822resized

Oregon Bio is also offering a special promotion to potential new members - Bio in the High Desert attendance fees can be applied toward new membership fees until June 18, 2015.

Special thanks to our Bio in the High Desert Sponsors!

vwrLogo      commission agents logo     

__________________________________

 

News Flash

  • 23andMe's plan to harness data for disease treatments

    Earlier this year, 23andMe announced it would be starting a new business.

    The nearly 10-year-old biotechnology company headquartered in Mountain View, California formed a new therapeutics division, which would be responsible for using 23andMe’s large database of genetic information to discover and develop drugs for a litany of diseases, according to Time Magazine.

    Richard Scheller, an experienced research and development executive from Genentech, was hired by 23andMe in March to run this new part of the firm.

    23andMe amassed genetic data from 900,000 customers after spending several years selling saliva-based genetic tests, although Time notes only 80 percent had agreed to have their information used for medical research.

    Scheller told Time this specific database is where he wanted to find any discernible clues that could lead to new therapies.

    The Role of Data Analysis

    In April, 23andMe hired Dr. Robert Gentleman as its vice president of computational biology to help put this plan into action.

    Dr. Gentleman is a noted expert in bioinformatics, and his role involves devising a number of data-oriented methods to help the therapeutics team efficiently sort through all genetic profiles and quickly find any actionable targets for potential drugs.

    "I came to 23andMe because it gave me the opportunity for a different take on drug development — one based more directly on genetics,” Dr. Gentleman said exclusively to Bioscience Technology (BST) in a phone interview.

    Reuters reports that analyzing DNA is becoming an important part of the drug manufacturing process because the lower cost of genetic sequencing could potentially cut down on the time it would take to find new targets for treatment.

    Reuters cites Regeneron Pharmaceutical as a corporate entity who has found success with this approach. Regeneron has reportedly identified multiple gene targets, particularly one that plays a role in obesity, from its own database of 250,000 volunteers that it began building in January 2014.

    “Drug development is so risky, but 23andMe’s large database of genetic information provides us with substantial tools to identify strong opportunities to develop novel therapeutics,” said Dr. Gentleman. He explained to BST how 23andMe has an advantage over competitors in terms of the size of the archive he has at his disposal.

    23andMe’s Partnerships

    So far, the therapeutics team has two major medical research projects currently underway.

    In January, Genentech and 23andMe said they were working together on finding a cure for Parkinson’s over the next few years. 23andMe will conduct full genome sequencing on an estimated 3,000 people afflicted with the disease found in the database. The results of this investigation will be used by Genentech to find new therapeutic targets for the disorder.

    A few months later, Pfizer and 23andMe revealed they are enrolling participants in a year-long study of Lupus disease. 23andMe will do all of the necessary data collection and analysis. Once the experiment is completed, 23andMe will present the findings in 2016 to the researchers at Pfizer, who may use this insight to develop new drugs capable of treating the disease.

    The Road Ahead

    No specific details in regard to new partnerships or which diseases would be targeted were provided to BST, but 23andMe did say the therapeutics team will delve into the genetic database and search for the best treatment opportunities.

    Andy Page, the biotech firm’s president said to BST, “23andMe will always be a consumer-driven company and customer engagement remains one of our top priorities.” He emphasized how important consent of sharing information and feedback from the community found in the database is to the therapeutics division’s work.

    23andMe was ordered by the U.S. Food and Drug Administration (FDA) to stop marketing its saliva-based genetic tests in November 2013 because the agency said there was not enough evidence provided to validate claims about how accurately the tool could detect health conditions.

    Executives from the enterprise complied with the directive from the FDA and stopped offering the test in December 2013. The FDA conducted a thorough regulatory review process the following year while the company spent that time period offering ancestry kits and uninterpreted genetic information to interested consumers while also meeting with a bevy of pharmaceutical companies, according to FierceBiotech. Since then, executives have reoriented their entire structure and shifted the business to focus on the database at its center.

    Further progress was made in February 2015. Anne Wojcicki, the CEO of the company, published a blog post saying the FDA granted marketing authorization for a new genetic test aimed at detecting a disorder called Bloom’s Syndrome.

    The post noted this approval “gives 23andMe a regulatory framework for future submissions.” No specific details in regard to new partnerships or which diseases would be targeted were provided to BST, but 23andMe did say the therapeutics team will delve into the genetic database and search for the best treatment opportunities.

    Andy Page, the biotech firm’s president said to BST, “23andMe will always be a consumer-driven company and customer engagement remains one of our top priorities.” He emphasized how important consent of sharing information and feedback from the community found in the database is to the therapeutics division’s work.

    23andMe was ordered by the U.S. Food and Drug Administration (FDA) to stop marketing its saliva-based genetic tests in November 2013 because the agency said there was not enough evidence provided to validate claims about how accurately the tool could detect health conditions.

    Executives from the enterprise complied with the directive from the FDA and stopped offering the test in December 2013. The FDA conducted a thorough regulatory review process the following year while the company spent that time period offering ancestry kits and uninterpreted genetic information to interested consumers while also meeting with a bevy of pharmaceutical companies, according to FierceBiotech. Since then, executives have reoriented their entire structure and shifted the business to focus on the database at its center.

    Further progress was made in February 2015. Anne Wojcicki, the CEO of the company, published a blog post saying the FDA granted marketing authorization for a new genetic test aimed at detecting a disorder called Bloom’s Syndrome.

    The post noted this approval “gives 23andMe a regulatory framework for future submissions.”

    _____________________________________________________________
    05/28/2015
    Ryan Bushey, Associate Editor
    Bioscience Technology

Bioscience News

  • For as long as I can remember, I’ve known that research and biotechnology would be a large part of my life. Science has always been a passion of mine, and I was lucky to be guided into the laboratory at an early age. In 11th grade I met my mentor, Dr. Angela Crawley, when she was a post-doctoral fellow working in Dr. Jonathan Angel’s laboratory at the Ottawa Hospital Research Institute. Here, I was introduced Read More >

  • It takes 450 years, almost half of a century, for a plastic bottle to decompose. In 2012 about 32 million tons of plastic garbage was collected of which only nine percent was recycled. Through industrial biotechnology, innovators are creating greener alternatives to consumer and personal care products that are commonly made using petroleum. In their article, Biobased products popping up throughout the economy, Agri-Pulse highlights how biobased products are rising in popularity and provides several examples Read More >

  • Next month in Philadelphia at the BIO International Convention, BIO will be partnering with the National Science foundation (NSF) and the National Institutes of Health (NIH) to host the 2nd annual, newly-expanded BIO Innovation Zone. The Zone will feature Small Business Innovation Research (SBIR) funded early-stage biotech companies. The SBIR/STTR program provides U.S. federal funding to small businesses engaged in research with the potential for commercialization. Each of the companies has been rigorously vetted through Read More >

Underwriting Sponsors

Sustaining Sponsors

Principal Sponsors

Home | Bio in Oregon | BioPro Training | Events | Sponsors | Member Resources | News | About Us

Oregon Bioscience Association Copyright © 2014. All Rights Reserved.